(News Bulletin 247) – Eli Lilly today announced the signing of a definitive agreement relating to its proposed acquisition of Versanis, a private biopharmaceutical company interested in the development of new drugs for the treatment of cardiovascular diseases. metabolic.
The main active ingredient in Versanis is bimagrumab, a monoclonal antibody that blocks activin and myostatin signaling. Bimagrumab is currently being evaluated in a phase 2b study, alone and in combination with semaglutide, in overweight or obese adults.
“By uniting the knowledge and expertise in incretin biology of Eli Lilly with the deep understanding of activin biology at Versanis, we aim to exploit the potential benefits of such combinations in patients,” said Ruth Gimeno. , group vice president of diabetes, obesity and cardiometabolic research at Eli Lilly.
Under the terms of the agreement, Versanis shareholders could receive up to $1.925 billion in cash, including an upfront payment and subsequent payments upon the achievement of certain development and sale milestones.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
